Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...

Novavax, Inc. (NASDAQ:NVAX ... the potential for Matrix-M to improve the activity of existing vaccines as in the case of ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...

(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi.

On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax (NVAX) shares dropped Tuesday morning after the company slashed its ...